



Clinical trial results:

A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan

Summary

EudraCT number	2008-004767-19
Trial protocol	Outside EU/EEA
Global end of trial date	13 March 2009

Results information

Result version number	v1 (current)
This version publication date	29 June 2016
First version publication date	18 July 2015

Trial information

Trial identification

Sponsor protocol code	6096A1-3003
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00574795
WHO universal trial number (UTN)	-
Other trial identifiers	Alias: B1851105

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800 7181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800 7181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 November 2009
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	13 March 2009
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the immune response to the 13 pneumococcal conjugates (1, 3, 4, 5, 6A, 6B, 7F,9V, 14, 18C, 19A, 19F, and 23F) induced by 13 valent pneumococcal conjugate vaccine (13vPnC) when measured 1 month after the infant series.

To evaluate the acceptability of the safety profile of 13vPnC as measured by the incidence rates of local reactions, systemic events, and adverse events (AEs).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 September 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Japan: 193
Worldwide total number of subjects	193
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	193
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

Subjects were recruited in Japan from September 2007 to February 2008.

Pre-assignment

Screening details:

Subjects were enrolled into the study according to inclusion/exclusion criteria without a screening period.

Period 1

Period 1 title	Infant Series
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	13vPnC Infant Series
------------------	----------------------

Arm description:

Subjects received one single dose of 13vPnC at approximately 2, 4 and 6 months of age.

Arm type	Experimental
Investigational medicinal product name	13vPnC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received 1 single 0.5 milliliter (mL) dose of 13vPnC at 2, 4, and 6 months of age.

Number of subjects in period 1	13vPnC Infant Series
Started	193
Vaccinated Dose 1	193
Vaccinated Dose 2	190
Vaccinated Dose 3	190
Completed	188
Not completed	5
Consent withdrawn by subject	2
Adverse Event	1
Protocol Violation	2

Period 2

Period 2 title	After Infant Series
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	13vPnC After Infant Series
------------------	----------------------------

Arm description:

Included subjects who received 1 single dose of 13vPnC at 2, 4, and 6 months of age.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 2	13vPnC After Infant Series
Started	188
Completed	185
Not completed	3
Consent withdrawn by subject	1
Adverse Event	2

Period 3

Period 3 title	Toddler Dose
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	13vPnC Toddler Dose
------------------	---------------------

Arm description:

Subjects received one single dose of 13vPnC at 12-15 months of age.

Arm type	Experimental
Investigational medicinal product name	13vPnC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received 1 single 0.5 mL dose of 13vPnC at 12-15 months of age.

Number of subjects in period 3	13vPnC Toddler Dose
Started	185
Completed	184
Not completed	1
Consent withdrawn by subject	1

Baseline characteristics

Reporting groups

Reporting group title	13vPnC Infant Series
-----------------------	----------------------

Reporting group description:

Subjects received one single dose of 13vPnC at approximately 2, 4 and 6 months of age.

Reporting group values	13vPnC Infant Series	Total	
Number of subjects	193	193	
Age categorical Units: Subjects			
Age continuous Units: months arithmetic mean standard deviation	3.7 ± 1.5	-	
Gender categorical Units: Subjects			
Female	93	93	
Male	100	100	

End points

End points reporting groups

Reporting group title	13vPnC Infant Series
Reporting group description: Subjects received one single dose of 13vPnC at approximately 2, 4 and 6 months of age.	
Reporting group title	13vPnC After Infant Series
Reporting group description: Included subjects who received 1 single dose of 13vPnC at 2, 4, and 6 months of age.	
Reporting group title	13vPnC Toddler Dose
Reporting group description: Subjects received one single dose of 13vPnC at 12-15 months of age.	
Subject analysis set title	13vPnC Dose 1
Subject analysis set type	Safety analysis
Subject analysis set description: Subjects received one single 0.5mL dose of 13vPnC at approximately 2 months of age (infant series Dose 1).	
Subject analysis set title	13vPnC Dose 2
Subject analysis set type	Safety analysis
Subject analysis set description: Subjects received one single 0.5mL dose of 13vPnC at approximately 4 months of age (infant series Dose 2).	
Subject analysis set title	13vPnC Dose 3
Subject analysis set type	Safety analysis
Subject analysis set description: Subjects received one single 0.5mL dose of 13vPnC at approximately 6 months of age (infant series Dose 3).	
Subject analysis set title	13vPnC Toddler Dose
Subject analysis set type	Safety analysis
Subject analysis set description: Subjects received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose).	

Primary: Percentage of Subjects Achieving Antibody Level Greater Than or Equal to (\geq) 0.35 microgram per milliliter (mcg/mL) in the 13vPnC Group After the 3-Dose Infant Series

End point title	Percentage of Subjects Achieving Antibody Level Greater Than or Equal to (\geq) 0.35 microgram per milliliter (mcg/mL) in the 13vPnC Group After the 3-Dose Infant Series ^[1]
End point description: Percentages of subjects achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 mcg/mL along with the corresponding 95 percent (%) confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Evaluable immunogenicity population had valid and determinate assay results and had no other major protocol violations.	
End point type	Primary
End point timeframe: One month after 3-dose infant series (at 7 months of age)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	176			
Units: Percentage of subjects				
number (confidence interval 95%)				
Common Serotypes - Serotype 4	100 (97.9 to 100)			
Common Serotypes - Serotype 6B	98.3 (95.1 to 99.6)			
Common Serotypes - Serotype 9V	100 (97.9 to 100)			
Common Serotypes - Serotype 14	100 (97.9 to 100)			
Common Serotypes - Serotype 18C	100 (97.9 to 100)			
Common Serotypes - Serotype 19F	97.2 (93.5 to 99.1)			
Common Serotypes - Serotype 23F	97.7 (94.3 to 99.4)			
Additional Serotypes - Serotype 1	100 (97.9 to 100)			
Additional Serotypes - Serotype 3	100 (97.9 to 100)			
Additional Serotypes - Serotype 5	100 (97.9 to 100)			
Additional Serotypes - Serotype 6A	100 (97.9 to 100)			
Additional Serotypes - Serotype 7F	100 (97.9 to 100)			
Additional Serotypes - Serotype 19A	100 (97.9 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the 3-Dose Infant Series

End point title	Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the 3-Dose Infant Series
-----------------	--

End point description:

GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after 3-dose infant series (at 7 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	176			
Units: mcg/mL				
geometric mean (confidence interval 95%)				
Common Serotypes - Serotype 4	6.76 (6.02 to 7.59)			
Common Serotypes - Serotype 6B	4.77 (4.07 to 5.59)			
Common Serotypes - Serotype 9V	3.39 (3.03 to 3.78)			
Common Serotypes - Serotype 14	14.69 (13.26 to 16.26)			
Common Serotypes - Serotype 18C	3.68 (3.27 to 4.14)			
Common Serotypes - Serotype 19F	5.71 (4.9 to 6.65)			
Common Serotypes - Serotype 23F	2.57 (2.21 to 3)			
Additional Serotypes - Serotype 1	5.11 (4.48 to 5.82)			
Additional Serotypes - Serotype 3	2.87 (2.55 to 3.24)			
Additional Serotypes - Serotype 5	3.85 (3.42 to 4.33)			
Additional Serotypes - Serotype 6A	3.77 (3.35 to 4.25)			
Additional Serotypes - Serotype 7F	5.78 (5.19 to 6.45)			
Additional Serotypes - Serotype 19A	6.97 (6.25 to 7.77)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Antibody Level ≥ 0.35 mcg/mL in the 13vPnC Group After the Toddler Dose

End point title	Percentage of Subjects Achieving Antibody Level ≥ 0.35 mcg/mL in the 13vPnC Group After the Toddler Dose
-----------------	---

End point description:

Percentages of subjects achieving WHO predefined antibody threshold ≥ 0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the toddler dose (at 12 - 15 months of age)

End point values	13vPnC Toddler Dose			
Subject group type	Reporting group			
Number of subjects analysed	178			
Units: percentage of subjects				
number (confidence interval 95%)				
Common Serotypes - Serotype 4	100 (97.9 to 100)			
Common Serotypes - Serotype 6B	100 (97.9 to 100)			
Common Serotypes - Serotype 9V	100 (97.9 to 100)			
Common Serotypes - Serotype 14	100 (97.9 to 100)			
Common Serotypes - Serotype 18C	100 (97.9 to 100)			
Common Serotypes - Serotype 19F	98.9 (96 to 99.9)			
Common Serotypes - Serotype 23F	98.9 (96 to 99.9)			
Additional Serotypes - Serotype 1	100 (97.9 to 100)			
Additional Serotypes - Serotype 3	99.4 (96.9 to 100)			
Additional Serotypes - Serotype 5	100 (97.9 to 100)			
Additional Serotypes - Serotype 6A	100 (97.9 to 100)			
Additional Serotypes - Serotype 7F	100 (97.9 to 100)			
Additional Serotypes - Serotype 19A	100 (97.9 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Toddler Dose

End point title	Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Toddler Dose
-----------------	--

End point description:

GMC as measured by ELISA for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the toddler dose (at 12-15 months of age)

End point values	13vPnC Toddler Dose			
Subject group type	Reporting group			
Number of subjects analysed	178			
Units: mcg/mL				
geometric mean (confidence interval 95%)				
Common Serotypes - Serotype 4	9.7 (8.43 to 11.17)			
Common Serotypes - Serotype 6B	14.61 (12.52 to 17.05)			
Common Serotypes - Serotype 9V	4.49 (4 to 5.06)			
Common Serotypes - Serotype 14	16.33 (14.49 to 18.41)			
Common Serotypes - Serotype 18C	6.09 (5.34 to 6.95)			
Common Serotypes - Serotype 19F	12.2 (10.37 to 14.35)			
Common Serotypes - Serotype 23F	6.55 (5.53 to 7.75)			
Additional Serotypes - Serotype 1	9.85 (8.62 to 11.27)			
Additional Serotypes - Serotype 3	2.06 (1.83 to 2.32)			
Additional Serotypes - Serotype 5	7.31 (6.52 to 8.2)			
Additional Serotypes - Serotype 6A	11.03 (9.69 to 12.55)			
Additional Serotypes - Serotype 7F	8.31 (7.39 to 9.35)			
Additional Serotypes - Serotype 19A	15.97 (14.07 to 18.13)			

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-Specified Local Reactions

End point title	Percentage of Subjects Reporting Pre-Specified Local Reactions
-----------------	--

End point description:

Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimetres [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (greater than [$>$] 7.0 cm). Subjects may be represented in more than 1 category. The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of subjects reporting yes for at least 1 day or no for all days.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 7 days after each dose

End point values	13vPnC Dose 1	13vPnC Dose 2	13vPnC Dose 3	13vPnC Toddler Dose
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	193	190	190	185
Units: percentage of subjects				
number (not applicable)				
Tenderness - Any (n=165,156,147,143)	13.3	19.9	14.3	18.2
Tenderness - Significant (n=160,152,143,132)	0.6	0	0	0
Swelling - Any (n=176,173,165,163)	47.2	53.8	53.9	57.1
Swelling - Mild (n=174,171,163,154)	46	49.1	50.3	44.2
Swelling - Moderate (n=167,164,150,151)	14.4	28.7	29.3	36.4
Swelling - Severe (n=160,153,143,132)	0	1.3	0.7	2.3
Redness - Any (n=186,180,171,166)	74.2	74.4	67.8	68.1
Redness - Mild (n=183,179,162,156)	68.3	64.8	55.6	53.8
Redness - Moderate (n=170,168,157,155)	24.7	43.5	38.9	40.6
Redness - Severe (n=160,153,143,132)	0	1.3	0.7	1.5

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-Specified Systemic Events

End point title	Percentage of Subjects Reporting Pre-Specified Systemic Events
-----------------	--

End point description:

Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever >39 C but ≤ 40 C, fever > 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Subjects may be represented in more than 1 category. The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of subjects reporting yes for at least 1 day or no for all days.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 7 days after each dose

End point values	13vPnC Dose 1	13vPnC Dose 2	13vPnC Dose 3	13vPnC Toddler Dose
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	193	190	190	185
Units: percentage of subjects				
number (not applicable)				
Fever $\geq 37.5^{\circ}\text{C}$ (n=170,163,154,150)	32.9	33.1	40.3	50.7
Fever $\geq 38^{\circ}\text{C}$ but $\leq 39^{\circ}\text{C}$ (n=163,156,146,137)	6.7	12.2	10.3	20.4
Fever $>39^{\circ}\text{C}$ but $\leq 40^{\circ}\text{C}$ (n=161,153,143,133)	1.2	2.6	2.8	5.3
Fever $>40^{\circ}\text{C}$ (n=160,152,143,132)	0	0.7	0	0

Decreased appetite (n=163,158,144,138)	11.7	16.5	9.7	18.1
Irritability (n=170,166,149,140)	30.6	36.1	23.5	26.4
Increased sleep (n=175,160,153,139)	40.6	29.4	22.2	24.5
Decreased sleep (n=169,160,145,138)	21.3	23.1	15.9	12.3
Hives (n=160,152,143,132)	1.3	1.3	0.7	0
Medication to treat symptoms (n=160,153,145,135)	1.9	6.5	5.5	8.1
Medication to prevent symptoms (n=160,153,144,134)	0.6	3.3	2.1	3

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline through 1 month after last study vaccination (13 Months)

Adverse event reporting additional description:

Version was not captured, hence 0.0 is mentioned for dictionary version.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	0.0
--------------------	-----

Reporting groups

Reporting group title	13vPnC Infant Series
-----------------------	----------------------

Reporting group description:

Subjects received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).

Reporting group title	13vPnC Post-Infant Series
-----------------------	---------------------------

Reporting group description:

Subjects received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).

Reporting group title	13vPnC Toddler Dose
-----------------------	---------------------

Reporting group description:

Subjects received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 12-15 months (toddler dose).

Serious adverse events	13vPnC Infant Series	13vPnC Post-Infant Series	13vPnC Toddler Dose
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 193 (4.66%)	14 / 193 (7.25%)	1 / 185 (0.54%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Subdural haematoma			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Febrile convulsion			
subjects affected / exposed	0 / 193 (0.00%)	2 / 193 (1.04%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Vomiting			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	1 / 185 (0.54%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchiolitis			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	2 / 193 (1.04%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis staphylococcal			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exanthema subitum			

subjects affected / exposed	1 / 193 (0.52%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 193 (0.52%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 193 (0.00%)	2 / 193 (1.04%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pertussis			
subjects affected / exposed	0 / 193 (0.00%)	2 / 193 (1.04%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			

subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis infectious			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	13vPnC Infant Series	13vPnC Post-Infant Series	13vPnC Toddler Dose
Total subjects affected by non-serious adverse events			
subjects affected / exposed	192 / 193 (99.48%)	19 / 193 (9.84%)	171 / 185 (92.43%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lymphangioma			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences (all)	0	1	0
Fibroma			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	163 / 193 (84.46%)	0 / 193 (0.00%)	115 / 185 (62.16%)
occurrences (all)	554	0	172
Injection site swelling			

subjects affected / exposed	121 / 193 (62.69%)	0 / 193 (0.00%)	94 / 185 (50.81%)
occurrences (all)	394	0	142
Pyrexia			
subjects affected / exposed	108 / 193 (55.96%)	0 / 193 (0.00%)	80 / 185 (43.24%)
occurrences (all)	218	0	115
Irritability			
subjects affected / exposed	93 / 193 (48.19%)	0 / 193 (0.00%)	38 / 185 (20.54%)
occurrences (all)	170	0	44
Injection site pain			
subjects affected / exposed	49 / 193 (25.39%)	0 / 193 (0.00%)	27 / 185 (14.59%)
occurrences (all)	76	0	27
Injection site induration			
subjects affected / exposed	16 / 193 (8.29%)	0 / 193 (0.00%)	2 / 185 (1.08%)
occurrences (all)	19	0	2
Injection site mass			
subjects affected / exposed	3 / 193 (1.55%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	3	0	1
Injection site irritation			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Injection site warmth			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Swelling			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Vaccination site induration			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Vessel puncture site reaction			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Injection site eczema			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Fever $\geq 38^{\circ}\text{C}$ but $\leq 39^{\circ}\text{C}$ (mild)	Additional description: Subjects affected and occurrences for SE is same as		

<p>Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[1]</p> <p>occurrences (all)</p>	data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	11 / 163 (6.75%)	0 / 193 (0.00%)	28 / 137 (20.44%)
	11	0	28
<p>Any fever ($\geq 37.5^{\circ}\text{C}$) Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[2]</p> <p>occurrences (all)</p>	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	56 / 170 (32.94%)	0 / 193 (0.00%)	76 / 150 (50.67%)
	56	0	76
<p>Fever $>39^{\circ}\text{C}$ but $\leq 40^{\circ}\text{C}$ (moderate) Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[3]</p> <p>occurrences (all)</p>	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	2 / 161 (1.24%)	0 / 193 (0.00%)	7 / 133 (5.26%)
	2	0	7
<p>Decreased appetite Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[4]</p> <p>occurrences (all)</p>	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination		
	19 / 163 (11.66%)	0 / 193 (0.00%)	25 / 138 (18.12%)
	19	0	25
<p>Irritability Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[5]</p> <p>occurrences (all)</p>	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	52 / 170 (30.59%)	0 / 193 (0.00%)	37 / 140 (26.43%)
	52	0	37
<p>Increased sleep Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[6]</p> <p>occurrences (all)</p>	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	71 / 175 (40.57%)	0 / 193 (0.00%)	34 / 139 (24.46%)
	71	0	34

Decreased sleep Infant Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[7] occurrences (all)	36 / 169 (21.30%) 36	0 / 193 (0.00%) 0	17 / 138 (12.32%) 17
Any fever (>=37.5°C) Infant Series Dose 2	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[8] occurrences (all)	54 / 163 (33.13%) 54	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Fever >=38°C but <=39°C (mild) Infant Series Dose 2	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[9] occurrences (all)	19 / 156 (12.18%) 19	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Fever >39°C but <=40°C (moderate) Infant Series Dose 2	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[10] occurrences (all)	4 / 153 (2.61%) 4	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Fever >40°C Dose Infant Series Dose 2	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[11] occurrences (all)	1 / 152 (0.66%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Decreased appetite Infant Series Dose 2	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[12] occurrences (all)	26 / 158 (16.46%) 26	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0

Irritability Infant Series Dose 2	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[13] occurrences (all)	60 / 166 (36.14%) 60	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Increased sleep Infant Series Dose 2	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[14] occurrences (all)	47 / 160 (29.38%) 47	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Decreased sleep Infant Dose 2	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[15] occurrences (all)	37 / 160 (23.13%) 37	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Fever $\geq 38^{\circ}\text{C}$ but $\leq 39^{\circ}\text{C}$ Infant Series Dose 3	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[16] occurrences (all)	15 / 146 (10.27%) 15	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Any fever ($\geq 37.5^{\circ}\text{C}$) Infant Series Dose 3	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[17] occurrences (all)	62 / 154 (40.26%) 62	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Fever $> 39^{\circ}\text{C}$ but $\leq 40^{\circ}\text{C}$ Infant Series Dose 3	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[18] occurrences (all)	4 / 143 (2.80%) 4	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0

Decreased appetite Infant Series Dose 3 alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[19] occurrences (all)	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	14 / 144 (9.72%) 14	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Irritability Infant Series Dose 3 alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[20] occurrences (all)	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	35 / 149 (23.49%) 35	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Increased sleep Infant Series Dose 3 alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[21] occurrences (all)	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	34 / 153 (22.22%) 34	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Decreased sleep Infant Dose 3 alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[22] occurrences (all)	Additional description: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	23 / 145 (15.86%) 23	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Immune system disorders Food allergy subjects affected / exposed occurrences (all) Milk allergy subjects affected / exposed occurrences (all) Solvent sensitivity subjects affected / exposed occurrences (all)	3 / 193 (1.55%) 3	8 / 193 (4.15%) 8	0 / 185 (0.00%) 0
	1 / 193 (0.52%) 2	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Reproductive system and breast disorders			

Balanoposthitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Rhinorrhoea			
subjects affected / exposed	13 / 193 (6.74%)	0 / 193 (0.00%)	8 / 185 (4.32%)
occurrences (all)	18	0	9
Asthma			
subjects affected / exposed	11 / 193 (5.70%)	4 / 193 (2.07%)	7 / 185 (3.78%)
occurrences (all)	14	5	7
Cough			
subjects affected / exposed	4 / 193 (2.07%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	4	0	1
Upper respiratory tract inflammation			
subjects affected / exposed	8 / 193 (4.15%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	13	0	1
Dysphonia			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Rhinitis allergic			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Wheezing			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Epistaxis			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Fibrinous bronchitis			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Psychiatric disorders			

Insomnia subjects affected / exposed occurrences (all)	66 / 193 (34.20%) 111	0 / 193 (0.00%) 0	17 / 185 (9.19%) 18
Head banging subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Investigations Liver function test abnormal subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Injury, poisoning and procedural complications Arthropod bite subjects affected / exposed occurrences (all)	3 / 193 (1.55%) 3	0 / 193 (0.00%) 0	3 / 185 (1.62%) 3
Contusion subjects affected / exposed occurrences (all)	2 / 193 (1.04%) 3	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Animal bite subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Excoriation subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	1 / 185 (0.54%) 1
Joint dislocation subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Joint injury subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 3	0 / 193 (0.00%) 0	1 / 185 (0.54%) 1
Skin laceration subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	2 / 185 (1.08%) 2
Thermal burn subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Clavicle fracture			

subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 185 (0.54%) 1
Mouth injury subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 185 (0.54%) 1
Congenital, familial and genetic disorders			
Dacryostenosis congenital subjects affected / exposed occurrences (all)	2 / 193 (1.04%) 2	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Cryptorchism subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	0 / 185 (0.00%) 0
Pectus excavatum subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	0 / 185 (0.00%) 0
Cardiac disorders			
Pulmonary valve stenosis subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Nervous system disorders			
Hypersomnia subjects affected / exposed occurrences (all)	101 / 193 (52.33%) 172	0 / 193 (0.00%) 0	34 / 185 (18.38%) 37
Crying subjects affected / exposed occurrences (all)	2 / 193 (1.04%) 2	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Blood and lymphatic system disorders			
Iron deficiency anaemia subjects affected / exposed occurrences (all)	2 / 193 (1.04%) 2	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Ear and labyrinth disorders			
Cerumen impaction subjects affected / exposed occurrences (all)	2 / 193 (1.04%) 2	0 / 193 (0.00%) 0	2 / 185 (1.08%) 2
Eye disorders			

Conjunctivitis			
subjects affected / exposed	16 / 193 (8.29%)	0 / 193 (0.00%)	8 / 185 (4.32%)
occurrences (all)	18	0	8
Eye discharge			
subjects affected / exposed	3 / 193 (1.55%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	4	0	1
Keratitis			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Ocular hyperaemia			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	32 / 193 (16.58%)	0 / 193 (0.00%)	12 / 185 (6.49%)
occurrences (all)	35	0	12
Constipation			
subjects affected / exposed	7 / 193 (3.63%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	7	0	1
Vomiting			
subjects affected / exposed	4 / 193 (2.07%)	1 / 193 (0.52%)	2 / 185 (1.08%)
occurrences (all)	4	1	2
Anal fissure			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	2 / 185 (1.08%)
occurrences (all)	1	0	2
Umbilical hernia			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Enterocolitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Haematochezia			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			

Liver disorder subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 185 (0.00%) 0
Skin and subcutaneous tissue disorders			
Tenderness (Any) Infant Series Dose 1 and Toddler Dose alternative dictionary used: Local Reactions 0.0 alternative assessment type: Systematic subjects affected / exposed ^[23] occurrences (all)	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination. 22 / 165 (13.33%) 22	0 / 193 (0.00%) 0	26 / 143 (18.18%) 26
Tenderness (Significant) Infant Series Dose 1 and Toddler Dose alternative dictionary used: Local Reactions 0.0 alternative assessment type: Systematic subjects affected / exposed ^[24] occurrences (all)	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination. 1 / 160 (0.63%) 1	0 / 193 (0.00%) 0	0 / 132 (0.00%) 0
Induration (Any) Infant Series Dose 1 and Toddler Dose alternative dictionary used: Local Reactions 0.0 alternative assessment type: Systematic subjects affected / exposed ^[25] occurrences (all)	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination. 83 / 176 (47.16%) 83	0 / 193 (0.00%) 0	93 / 163 (57.06%) 93
Induration (Mild) Infant Series Dose 1 and Toddler Dose alternative dictionary used: Local Reactions 0.0 alternative assessment type: Systematic subjects affected / exposed ^[26] occurrences (all)	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination. 80 / 174 (45.98%) 80	0 / 193 (0.00%) 0	68 / 154 (44.16%) 68
Induration (Moderate) Infant Series Dose 1 and Toddler Dose alternative dictionary used: Local Reactions 0.0 alternative assessment type: Systematic subjects affected / exposed ^[27] occurrences (all)	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination 24 / 167 (14.37%) 24	0 / 193 (0.00%) 0	55 / 151 (36.42%) 55
Induration (Severe) Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination		

subjects affected / exposed ^[28]	0 / 160 (0.00%)	0 / 193 (0.00%)	3 / 132 (2.27%)
occurrences (all)	0	0	3
Erythema (Any) Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[29]	138 / 186 (74.19%)	0 / 193 (0.00%)	113 / 166 (68.07%)
occurrences (all)	138	0	113
Erythema (Mild) Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[30]	125 / 183 (68.31%)	0 / 193 (0.00%)	84 / 156 (53.85%)
occurrences (all)	125	0	84
Erythema (Moderate) Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[31]	42 / 170 (24.71%)	0 / 193 (0.00%)	63 / 155 (40.65%)
occurrences (all)	42	0	63
Erythema (Severe) Infant Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[32]	0 / 160 (0.00%)	0 / 193 (0.00%)	2 / 132 (1.52%)
occurrences (all)	0	0	2
Tenderness (Any) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[33]	31 / 156 (19.87%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	31	0	0
Induration (Any) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed ^[34]	93 / 173 (53.76%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	93	0	0
Induration (Mild) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[35]	84 / 171 (49.12%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	84	0	0
Induration (Moderate) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[36]	47 / 164 (28.66%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	47	0	0
Induration (Severe) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[37]	2 / 153 (1.31%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Erythema (Any) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[38]	134 / 180 (74.44%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	134	0	0
Erythema (Mild) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[39]	116 / 179 (64.80%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	116	0	0
Erythema (Moderate) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed ^[40]	73 / 168 (43.45%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	73	0	0
Erythema (Severe) Infant Series Dose 2	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[41]	2 / 153 (1.31%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Tenderness (Any) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[42]	21 / 147 (14.29%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	21	0	0
Induration (Any) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[43]	89 / 165 (53.94%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	89	0	0
Induration (Mild) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[44]	82 / 163 (50.31%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	82	0	0
Induration (Moderate) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[45]	44 / 150 (29.33%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	44	0	0
Induration (Severe) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed ^[46]	1 / 143 (0.70%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Erythema (Any) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[47]	116 / 171 (67.84%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	116	0	0
Erythema (Mild) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[48]	90 / 162 (55.56%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	90	0	0
Erythema (Moderate) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[49]	61 / 157 (38.85%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	61	0	0
Erythema (Severe) Infant Series Dose 3	Additional description: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[50]	1 / 143 (0.70%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Dermatitis diaper			
subjects affected / exposed	27 / 193 (13.99%)	0 / 193 (0.00%)	4 / 185 (2.16%)
occurrences (all)	30	0	4
Eczema			
subjects affected / exposed	24 / 193 (12.44%)	0 / 193 (0.00%)	10 / 185 (5.41%)
occurrences (all)	28	0	10
Rash			
subjects affected / exposed	14 / 193 (7.25%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	16	0	1
Eczema infantile			

subjects affected / exposed	8 / 193 (4.15%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	9	0	1
Urticaria			
subjects affected / exposed	7 / 193 (3.63%)	0 / 193 (0.00%)	4 / 185 (2.16%)
occurrences (all)	8	0	4
Dry skin			
subjects affected / exposed	6 / 193 (3.11%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	6	0	0
Erythema			
subjects affected / exposed	6 / 193 (3.11%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	12	0	0
Heat rash			
subjects affected / exposed	6 / 193 (3.11%)	0 / 193 (0.00%)	8 / 185 (4.32%)
occurrences (all)	7	0	8
Petechiae			
subjects affected / exposed	4 / 193 (2.07%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	4	0	0
Dermatitis atopic			
subjects affected / exposed	3 / 193 (1.55%)	2 / 193 (1.04%)	0 / 185 (0.00%)
occurrences (all)	3	2	0
Dermatitis			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Hyperkeratosis			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Asteatosis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Blister			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Dermatitis contact			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Drug eruption			

subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Eczema asteatotic			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	1	0	1
Pruritus			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	1	0	1
Rash erythematous			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Vesicoureteric reflux			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	77 / 193 (39.90%)	0 / 193 (0.00%)	42 / 185 (22.70%)
occurrences (all)	121	0	48
Nasopharyngitis			
subjects affected / exposed	41 / 193 (21.24%)	0 / 193 (0.00%)	15 / 185 (8.11%)
occurrences (all)	66	0	17
Bronchitis			
subjects affected / exposed	24 / 193 (12.44%)	1 / 193 (0.52%)	12 / 185 (6.49%)
occurrences (all)	36	1	12
Exanthema subitum			
subjects affected / exposed	24 / 193 (12.44%)	0 / 193 (0.00%)	7 / 185 (3.78%)
occurrences (all)	24	0	7
Gastroenteritis			

subjects affected / exposed	19 / 193 (9.84%)	0 / 193 (0.00%)	5 / 185 (2.70%)
occurrences (all)	23	0	5
Influenza			
subjects affected / exposed	9 / 193 (4.66%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	9	0	1
Pharyngitis			
subjects affected / exposed	9 / 193 (4.66%)	0 / 193 (0.00%)	8 / 185 (4.32%)
occurrences (all)	11	0	9
Varicella			
subjects affected / exposed	9 / 193 (4.66%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	9	0	1
Rhinitis			
subjects affected / exposed	7 / 193 (3.63%)	0 / 193 (0.00%)	3 / 185 (1.62%)
occurrences (all)	7	0	3
Enteritis infectious			
subjects affected / exposed	5 / 193 (2.59%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	7	0	1
Otitis media			
subjects affected / exposed	5 / 193 (2.59%)	1 / 193 (0.52%)	10 / 185 (5.41%)
occurrences (all)	6	2	10
Otitis media acute			
subjects affected / exposed	5 / 193 (2.59%)	0 / 193 (0.00%)	4 / 185 (2.16%)
occurrences (all)	11	0	4
Bronchiolitis			
subjects affected / exposed	4 / 193 (2.07%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	4	0	1
Croup infectious			
subjects affected / exposed	4 / 193 (2.07%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	5	0	0
Gastroenteritis viral			
subjects affected / exposed	4 / 193 (2.07%)	0 / 193 (0.00%)	4 / 185 (2.16%)
occurrences (all)	4	0	4
Molluscum contagiosum			
subjects affected / exposed	4 / 193 (2.07%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	4	0	1
Adenovirus infection			

subjects affected / exposed	3 / 193 (1.55%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	3	0	1
Respiratory syncytial virus infection			
subjects affected / exposed	3 / 193 (1.55%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	3	0	0
Conjunctivitis bacterial			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	3	0	0
Fungal skin infection			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Gastroenteritis rotavirus			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Respiratory tract infection			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	3	0	0
Skin candida			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Viral rash			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Cellulitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Enterocolitis viral			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Enterovirus infection			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Herpes simplex			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Impetigo			

subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	2 / 185 (1.08%)
occurrences (all)	1	0	2
Laryngitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Omphalitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Paronychia			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Pertussis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Rotavirus infection			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Subcutaneous abscess			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Viral diarrhoea			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	1	0	0
Viral infection			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	1	0	1

Herpangina			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	4 / 185 (2.16%)
occurrences (all)	0	0	4
Adenoviral upper respiratory infection			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Bronchopneumonia			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Enterocolitis infectious			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	2
Gastroenteritis bacterial			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Tonsillitis			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	47 / 193 (24.35%)	0 / 193 (0.00%)	25 / 185 (13.51%)
occurrences (all)	66	0	26
Dehydration			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 185 (0.00%)
occurrences (all)	2	0	0
Lactose intolerance			
subjects affected / exposed	2 / 193 (1.04%)	1 / 193 (0.52%)	0 / 185 (0.00%)
occurrences (all)	2	1	0
Hypocalcaemia			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 185 (0.54%)
occurrences (all)	0	0	1

Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 November 2008	A clarification was added to ensure that before the study closeout visit at each site, the investigator provided the sponsor with follow-up information on any AEs that had been ongoing at a subject's last visit.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported